The 45 linked references in paper E. Prokopenko I., A. Vatazin V., E. Shcherbakova O., Е. Прокопенко И., А. Ватазин В., Е. Щербакова О. (2017) “ТРАНСПЛАНТАЦИЯ ПОЧКИ У ПАЦИЕНТОВ С АТИПИЧНЫМ ГЕМОЛИТИКО-УРЕМИЧЕСКИМ СИНДРОМОМ (лекция) // KIDNEY TRANSPLANTATION IN PATIENTS WITH ATYPICAL HAEMOLYTIC URAEMIC SYNDROME (lection)” / spz:neicon:nefr:y:2016:i:6:p:111-118

  1. Constantinescu AR, Bitzan M, Weiss LS et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis 2004;43: 976–982. doi: 10.1053/j. ajkd.2004.02.010
  2. Sullivan M, Erlic Z, Hoffmann MM et al. Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome. Ann Hum Genet 2010;74:17–26. doi: 10.1111/j.1469-1809.2009.00554.x
  3. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:60. doi: 10.1186/17501172-6-60
  4. Zuber J, Fakhouri F, Roumenina LT et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012;8(11):643-657. doi: 10.1038/ nrneph.2012.214
  5. Davin JC, Buter N, Groothoff J et al. Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndrome. Pediatr Nephrol 2009;24(9):1757-1760. doi: 10.1007/ s00467-009-1188-8
  6. Le Quintrec M, Zuber J, Moulin B et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013;13(3):663-675. doi: 10.1111/ajt.12077
  7. Davin JC, van de Kar N. Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Ther Adv Hematol 2015;6(4): 171–185. doi: 10.1177/2040620715577613
  8. Campistol JM, Arias M, Ariceta G et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2015;35(5):421-447. doi: 10.1016/j.nefro.2015.07.005
  9. Ferraris JR, Ramirez JA, Ruiz S et al. Shiga toxin-associated hemolytic uremic syndrome: absence of recurrence after renal transplantation. Pediatr Nephrol 2002;17(10):809-814. doi: 10.1007/s00467-002-0936-9
  10. doi: 10.1016/j.trre.2013.07.003 12. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007;18(8): 2392-2400. doi: 10.1681/ASN.2006080811
  11. Raedler H, Heeger PS. Complement regulation of T-cell alloimmunity. Curr Opin Organ Transplant 2011;16(1):54-60. doi: 10.1097/MOT.0b013e3283425419
  12. Ažukaitis K, Loirat C, Malina M et al. Macrovascular involvement in a child with atypical hemolytic uremic syndrome. Pediatr Nephrol 2014; 29(7):1273-1277. doi: 10.1007/s00467013-2713-3
  13. Licht C, Ardissino G, Ariceta G et al. 1.The global aHUS registry: methodology and initial patient characteristics. BMC Nephrol 2015;16:207. doi: 10.1186/s12882-015-0195-1
  14. Noris M, Caprioli J, Bresin E et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010;5:1844–1859. doi: 10.2215/CJN.02210310
  15. Zuber J, le Quintrec M, Sberro-Soussan R et al. New insights into postrenal transplant hemolytic uremic syndrome. NatRev Nephrol 2011;7:23–35. doi: 10.1038/nrneph.2010.155
  16. Venables JP, Strain L, Routledge D et al. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 2006;3:e431. doi: 10.1371/journal.pmed.0030431
  17. 9; 114:2837–2845. doi: 10.1182/blood-2009-01-197640 20. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA 2007;104:240–245. doi: 10.1073/pnas.0603420103
  18. Bresin E, Daina E, Noris M et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 2006;1:88–99. doi: 10.2215/ CJN.00050505
  19. Loirat C, Fremeaux-Bacchi V. Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr Transplant 2008;12: 619–629. doi: 10.1111/j.1399-3046.2008.00910
  20. Le Quintrec M, Zuber J, Noel LH et al. Anti-factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome. Am J Transplant 2009;9:1223–1229. doi: 10.1111/j.1600-6143.2009.02586
  21. Dragon-Durey MA, Sethi SK, Bagga A et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010; 21:2180–2187. doi: 10.1681/ ASN.2010030315
  22. Werkhoven MB, Damman J, van Dijk MC et al. Complement mediated renal inflammation induced by donor brain death: role of renal C5a-C5aR interaction. Am J Transplant 2013;13(4): 875-882. doi: 10.1111/ajt.12130
  23. Błogowski W, Dołęgowska B, Sałata D et al. Clinical analysis of perioperative complement activity during ischemia/ reperfusion injury following renal transplantation. Clin J Am Soc Nephrol 2012;7(11):1843-1851. doi: 10.2215/CJN.02200312
  24. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009;4(2):481-508. doi: 10.2215/CJN.04800908
  25. Lovric S, Kielstein JT, Kayser D et al. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series. Nephrol Dial Transplant 2011;26(9):3032-3038. doi: 10.1093/ndt/gfq842
  26. Noone D, Al-Matrafi J, Tinckam K et al. Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. Am J Transplant 2012;12(9):2546-2553. doi: 10.1111/j.1600-6143.2012.04124
  27. Le Quintrec M, Lionet A, Kamar N et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 2008;8(8):1694-1701. doi: 10.1111/j.1600-6143.2008.02297
  28. Wilson CH, Brown AL, White SA et al. Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab. Transplantation 2011;92(8):e42-43. doi: 10.1097/ TP.0b013e318230c0bd
  29. Bruneau S, Néel M, Roumenina LT et al. Loss of DGK induces endothelial cell activation and death independently of complement activation. Blood 2015;125(6):1038-1046. doi: 10.1182/blood-2014-06-579953
  30. Loirat C, Saland J, Bitzan M. Management of hemolytic uremic syndrome. Presse Med 2012;41(3 Pt 2):e115-135. doi: 10.1016/j.lpm.2011.11.013
  31. Saland JM, Ruggenenti P, Remuzzi G; Consensus Study Group. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 2009;20(5):940-949. doi: 10.1681/ASN.2008080906
  32. Koskinen AR, Tukiainen E, Arola J et al. Complement activation during liver transplantation-special emphasis on patients with atypical hemolytic uremic syndrome. Am J Transplant 2011;11(9):1885-1895. doi: 10.1111/j.1600-6143.2011.03612
  33. Saland JM, Shneider BL, Bromberg JS et al. Successful split liver–kidney transplant for factor H associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009;4:201–206. doi: 10.2215/CJN.02170508
  34. Wilson C, Torpey N, Jaques B et al. Successful simultaneous liver-kidney transplant in an adult with atypical hemolytic uremic syndrome associated with a mutation in complement factor H. Am J Kidney Dis 2011;58(1):109-112. doi: 10.1053/j. ajkd.2011.04.008
  35. Tran H, Chaudhuri A, Concepcion W, Grimm PC. Use of eculizumab and plasma exchange in successful combined liverkidney transplantation in a case of atypical HUS associated with complement factor H mutation. Pediatr Nephrol 2014;29(3):477480. doi: 10.1007/s00467-013-2630-5
  36. Chatelet V, Frémeaux-Bacchi V, Lobbedez T et al. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009;9(11):2644-2645. doi: 10.1111/j.16006143.2009.02817
  37. Zimmerhackl LB, Hofer J, Cortina G et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010;362(18):1746-1748. doi: 10.1056/ NEJMc1001060
  38. Weitz M, Amon O, Bassler D et al. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 2011;26(8):1325-1329. doi: 10.1007/ s00467-011-1879-9
  39. Román-Ortiz E, Mendizabal Oteiza S, Pinto S et al. Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene. Pediatr Nephrol 2014;29(1):149-153. doi: 10.1007/s00467-013-2591-8
  40. Zuber J, Le Quintrec M, Krid S et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012;12(12):3337-3354. doi: 10.1111/j.16006143.2012.04252
  41. Matar D, Naqvi F, Racusen LC et al. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation 2014;98(11):1205-1212. doi: 10.1097/ TP.0000000000000200
  42. Broeders EN, Stordeur P, Rorive S, Dahan K. A ‘silent’, new polymorphism of factor H and apparent de novo atypical haemolytic uraemic syndrome after kidney transplantation. BMJ Case Rep 2014 Dec 23;2014. pii: bcr2014207630. doi: 10.1136/ bcr-2014-207630
  43. Teixeira CI, Mota RG, Afonso BG et al. Use of Eculizumab in atypical hemolytic uremic syndrome after renal transplantation. J Bras Nefrol 2015;37(1):127-130. doi: 10.5935/01012800.20150018
  44. Struijk GH, Bouts AH, Rijkers GT et al. Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant 2013;13(3):819-820. doi: 10.1111/ajt.12032
  45. Zlamy M, Hofer J, Elias J, Vogel U. Immunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy. Pediatr Transplant 2012;16(6):E246-250. doi: 10.1111/j.1399-3046.2011.01585.x